Table 2 Hazard ratios for outcomes in patients with T2D with and without GLP-1 RAs

From: Effects of glucagon-like peptide-1 receptor agonists on liver-related and cardiovascular mortality in patients with type 2 diabetes

Outcome	T2D patients without GLP-1 RA			T2D patients with GLP-1 RA
Outcome	n	PY	IR	n	PY	IR	cHR	aHR¹	aHR²	aHR³	aHR⁴	(95% CI)
All-cause mortality	1093	83691	13.06	480	84680	5.67	0.43	0.46	0.46	0.46	0.48	(0.43, 0.53)***
MACE	1653	80860	20.44	1486	82211	18.08	0.88	0.92	0.91	0.92	0.92	(0.86, 0.99)*
Cardiovascular death	197	83691	2.35	103	84680	1.22	0.52	0.55	0.54	0.55	0.57	(0.45, 0.72)***
Liver-related death	22	83691	0.26	7	84680	0.08	0.31	0.36	0.35	0.35	0.32	(0.13, 0.75)**
Liver cirrhosis	155	83495	1.86	165	84421	1.95	1.05	1.08	1.08	1.08	1.10	(0.88, 1.37)
Hepatic failure	71	83603	0.85	63	84596	0.74	0.87	0.90	0.89	0.90	0.92	(0.66, 1.30)
Hepatocellular carcinoma	44	83685	0.53	41	84664	0.48	0.93	1.02	1.00	1.01	0.91	(0.59, 1.40)

T2D type 2 diabetes, GLP-1 RAs glucagon-like peptide-1 receptor agonists, PY person-years, IR incidence rate, per 1,000 person-years, cHR crude hazard ratio, aHR adjusted hazard ratio, MACE major adverse cardiovascular events; aHR¹: Adjusted for sex, and age; aHR²: Adjusted for sex, age, income, and obesity; aHR³: Adjusted for sex, age, income, obesity, and comorbidities; aHR⁴: adjusted for sex, age, income, obesity, comorbidities, medications, and duration of diabetes as shown in Table 1
^* P < 0.05
^** P < 0.01
^*** P < 0.001

Back to article page

ISSN: 1741-7015

Contact us

Submission enquiries: bmcmedicineeditorial@biomedcentral.com
General enquiries: info@biomedcentral.com